CluePoints, a provider of Centralized Statistical Monitoring (CSM) solutions for clinical trials, has secured an ENTENTE Life Science Investment Forum Award. The award program, which is organized by the ENTENTE project and supported by the European Commission and EuropaBio, recognized CluePoints as one of Belgium's most innovative high technology businesses for its Central Statistical Monitoring (CSM) solution, which employs unique statistical algorithms to determine the quality, accuracy and integrity of clinical trial data.
The Belgian edition of the ENTENTE Life Science Investment Forum united 28 European early stage innovative companies, selected from a pool of 100 companies making significant advances in the health sector. The selected companies pitched their innovations and developments to an international judging panel consisting of 50 venture capitalists, corporate investors and industry experts.
As a result of being selected for the Belgian ENTENTE award, CluePoints now has qualified to continue along the European Venture contest, a pan-European contest that brings together the top companies from each edition to join the European Venture Summit, taking place Dec. 8-9, 2015 in Dusseldorf, Germany.
"This award win is another real testament to the hard work and unwavering commitment from the CluePoints team," said Franҫois Torche, CEO of CluePoints. "We developed our monitoring solutions with a shared belief that we could make a real difference to the way that oversight is approached in clinical trials. We are absolutely delighted to have been recognized by ENTENTE for our efforts.”